Steward Partners Investment Advisory’s Heron Therapeutics HRTX Stock Holding History

Steward Partners Investment Advisory’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$800	Hold	1,000	–	–	﹤0.01%	4216
2025 Q4	$1.3K	Hold	1,000	–	–	﹤0.01%	4044
2025 Q3	$1.26K	Hold	1,000	–	–	﹤0.01%	4020
2025 Q2	$2.07K	Hold	1,000	–	–	﹤0.01%	3722
2025 Q1	$2.2K	Hold	1,000	–	–	﹤0.01%	3622
2024 Q4	$1.53K	Sell	1,000 -110	-10%	-$178	﹤0.01%	3694
2024 Q3	$2.21K	Sell	1,110 -26,415	-96%	-$63.1K	﹤0.01%	3422
2024 Q2	$96.3K	Buy	27,525 +26,525	+2,653%	+$81.5K	﹤0.01%	1802
2024 Q1	$2.77K	Hold	1,000	–	–	﹤0.01%	3226
2023 Q4	$1.7K	Hold	1,000	–	–	﹤0.01%	3233
2023 Q3	$1.03K	Hold	1,000	–	–	﹤0.01%	3186
2023 Q2	$1.16K	Hold	1,000	–	–	﹤0.01%	3111
2023 Q1	$1.51K	Hold	1,000	–	–	﹤0.01%	3069
2022 Q4	$2.5K	Hold	1,000	–	–	﹤0.01%	2973
2022 Q3	$4K	Hold	1,000	–	–	﹤0.01%	2852
2022 Q2	$3K	Hold	1,000	–	–	﹤0.01%	2915
2022 Q1	$6K	Hold	1,000	–	–	﹤0.01%	2825
2021 Q4	$9K	Hold	1,000	–	–	﹤0.01%	2644
2021 Q3	$11K	Hold	1,000	–	–	﹤0.01%	2571
2021 Q2	$16K	Sell	1,000 -6,912	-87%	-$110K	﹤0.01%	5394
2021 Q1	$128K	Buy	7,912 +6,912	+691%	+$123K	﹤0.01%	1502
2020 Q4	$21K	Sell	1,000 -500	-33%	-$8.69K	﹤0.01%	2034
2020 Q3	$22K	Hold	1,500	–	–	﹤0.01%	1857
2020 Q2	$22K	Hold	1,500	–	–	﹤0.01%	1731
2020 Q1	$17K	Buy	1,500 +500	+50%	+$9.4K	﹤0.01%	1666
2019 Q4	$23K	Hold	1,000	–	–	﹤0.01%	1727
2019 Q3	$18K	Hold	1,000	–	–	﹤0.01%	1759
2019 Q2	$18K	Buy	+1,000	New	+$20K	﹤0.01%	1746
2018 Q4	–	Sell	-1,000	Closed	-$32K	–	1372
2018 Q3	$32K	Hold	1,000	–	–	﹤0.01%	1360
2018 Q2	$39K	Hold	1,000	–	–	﹤0.01%	1197
2018 Q1	$27K	Hold	1,000	–	–	﹤0.01%	1222
2017 Q4	$18K	Buy	+1,000	New	+$16.3K	﹤0.01%	1159

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Steward Partners Investment Advisory's HRTX Position: Q1 2026 in Review

Steward Partners Investment Advisory held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 1,000 shares worth $800. The position accounts for ﹤0.01% of the portfolio, ranked #4216.

Steward Partners Investment Advisory first reported a position in HRTX in Q4 2017 and has held it in 32 quarters since. The position peaked at $128K in Q1 2021. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

Steward Partners Investment Advisory held 1,000 shares of Heron Therapeutics worth $800 as of Q1 2026.
Steward Partners Investment Advisory left its Heron Therapeutics share count unchanged in Q1 2026.
Heron Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #4216 holding.
Steward Partners Investment Advisory first reported a position in Heron Therapeutics in Q4 2017 and has held it in 32 quarters since.
Steward Partners Investment Advisory's Heron Therapeutics position peaked at $128K in Q1 2021.
167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.